Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,562,521
  • Shares Outstanding, K 79,458
  • Annual Sales, $ 517,150 K
  • Annual Income, $ 66,350 K
  • EBIT $ 60 M
  • EBITDA $ 78 M
  • 60-Month Beta 1.96
  • Price/Sales 4.98
  • Price/Cash Flow 21.75
  • Price/Book 1.96

Options Overview Details

View History
  • Implied Volatility 73.46% (+1.69%)
  • Historical Volatility 54.38%
  • IV Percentile 67%
  • IV Rank 46.63%
  • IV High 109.12% on 04/14/25
  • IV Low 42.30% on 08/13/25
  • Expected Move (DTE 14) 3.06 (9.49%)
  • Put/Call Vol Ratio 3.00
  • Today's Volume 4
  • Volume Avg (30-Day) 87
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 2,695
  • Open Int (30-Day) 3,122
  • Expected Range 29.19 to 35.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.23
  • Number of Estimates 4
  • High Estimate $0.24
  • Low Estimate $0.22
  • Prior Year $0.18
  • Growth Rate Est. (year over year) +27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.45 +9.49%
on 03/27/26
36.60 -11.90%
on 03/05/26
-3.76 (-10.44%)
since 03/02/26
3-Month
29.45 +9.49%
on 03/27/26
46.76 -31.02%
on 01/07/26
-10.14 (-23.92%)
since 01/02/26
52-Week
22.61 +42.64%
on 07/18/25
50.71 -36.40%
on 11/25/25
+2.12 (+7.04%)
since 04/02/25

Most Recent Stories

More News
Veracyte Names Kevin Haas as Chief Development and Technology Officer

Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership...

VCYT : 32.25 (-0.46%)
Veracyte: Q4 Earnings Snapshot

Veracyte: Q4 Earnings Snapshot

VCYT : 32.25 (-0.46%)
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% ...

VCYT : 32.25 (-0.46%)
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests

VCYT : 32.25 (-0.46%)
Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. ...

VCYT : 32.25 (-0.46%)
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on...

VCYT : 32.25 (-0.46%)
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Grew full-year revenue to between $515 million and $517 million, an increase of 16%

VCYT : 32.25 (-0.46%)
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at...

VCYT : 32.25 (-0.46%)
Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. ...

VCYT : 32.25 (-0.46%)
Veracyte: Q3 Earnings Snapshot

Veracyte: Q3 Earnings Snapshot

VCYT : 32.25 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 34.83
2nd Resistance Point 34.01
1st Resistance Point 33.13
Last Price 32.25
1st Support Level 31.42
2nd Support Level 30.60
3rd Support Level 29.72

See More

52-Week High 50.71
Fibonacci 61.8% 39.98
Fibonacci 50% 36.66
Fibonacci 38.2% 33.34
Last Price 32.25
52-Week Low 22.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.